From the Retinal and Oncology Service at S.t Erik’s Eye Hospital and Karolinska Institutet and
the Department of Oncology and Pathology, Division of Cellular and Molecular Tumor
Pathology, Karolinska Hospital and Karolinska Institutet, Stockholm, Sweden

UVEAL MELANOMA:
CYTOGENETICS, MOLECULAR BIOLOGY
AND TUMOR IMMUNOLOGY

Charlotta All-Ericsson

Stockholm 2002
All previously published papers were reproduced with permission from the publisher.

Published and printed by Karolinska University Press
Box 200, SE-171 77 Stockholm, Sweden
© Charlotta All-Ericsson, 2002
ISBN91-7349-278-7
To Carl-Fredrik and Christoffer
ABSTRACT

Uveal melanoma is the most common primary intraocular malignancy. The metastatic spread is hematogenous and exclusively to the liver. Although eye-sparing treatments are used more frequently the tumor-related mortality in uveal melanoma is still 30-50%. Only 2% of the patients have detectable metastases at the time of diagnosis. The aim of this study was to test various prognostic markers and possibly new treatment modalities.

Chromosomal aberrations were studied on 35 paraffin-embedded tumor specimens with comparative genomic hybridization (CGH) technique. 29 out of 35 tumors showed copy number changes. The most common losses were on chromosome 3, 6q, and 1p and the most common gains on chromosome 8q, 6p and 1q. The mean number of DNA copy number changes was significantly higher in the metastasizing tumors and metastases.

The expression of human leukocyte antigen (HLA) class I, beta-2-microglobulin and HLA class II were studied with immunohistochemistry (IHC) on 65 tumor samples. In all three groups high expression was correlated to an adverse clinical outcome.

The insulin-like growth factor-1 receptor (IGF-1R) has been implicated as an important factor for tumor progression in several different tumors. We could show by both IHC and Western blotting (WB) that IGF-1R is expressed in uveal melanoma. Furthermore we were able to induce cell growth arrest and cell death by using tunicamycin and lovastatin, which inhibit the N-linked glycosylation, and aIR-3 which blocks the binding domain of IGF-1R.

Previous studies have indicated that the proto-oncogene c-kit is important in tumor progression. We found when using IHC that 84 out of 134 (64%) tumors expressed c-kit. This result could be confirmed by WB where 6 out of 8 samples expressed c-kit. To study the anti-proliferative effects of the tyrosine kinase inhibitor STI571 we treated four uveal melanoma and two skin melanoma cell lines. Cell proliferation was completely inhibited after 48h by 0.1-1μM STI571 in the uveal melanoma cell lines but not in the skin melanoma cell lines.

In conclusion, this study suggests that chromosomal aberrations on chromosome 1, 3, 6 and 8, and expression of HLA may be used as prognostic markers and that the IGF-1R and c-kit may in the future be used as therapeutic targets.

KEY WORDS: Uveal melanoma, prognostic markers, treatment, CGH, chromosomal aberrations, HLA, IHC, Western blotting, IGF-1R, c-kit, STI571

ISBN 91-7349-278-7
LIST OF PAPERS

This thesis is based on the following papers, which will be referred to by their Roman numerals:


IV. All-Ericsson C, Girmai L, Brodin B, Seregard S, Östman A and Larsson O. Inhibition of proto-oncogene c-kit: a potential therapeutic target in metastasizing uveal melanoma (manuscript)

All papers are reprinted with permission from the Association for Research in Vision and Ophthalmology.
CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>1</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>2</td>
</tr>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Anatomy, history and treatment</td>
<td>4</td>
</tr>
<tr>
<td>Predisposing lesions</td>
<td>6</td>
</tr>
<tr>
<td>Prognosis</td>
<td>7</td>
</tr>
<tr>
<td>Prognostic factors</td>
<td>7</td>
</tr>
<tr>
<td>Tumor location</td>
<td>7</td>
</tr>
<tr>
<td>Extrascleral extension</td>
<td>7</td>
</tr>
<tr>
<td>Tumor size</td>
<td>7</td>
</tr>
<tr>
<td>Cell type</td>
<td>8</td>
</tr>
<tr>
<td>Proliferative activity</td>
<td>9</td>
</tr>
<tr>
<td>Vascular patterns</td>
<td>9</td>
</tr>
<tr>
<td>Immunology and eye</td>
<td>9</td>
</tr>
<tr>
<td>Chromosomal aberrations</td>
<td>11</td>
</tr>
<tr>
<td>Growth factors</td>
<td>11</td>
</tr>
<tr>
<td>Aims of the study</td>
<td>15</td>
</tr>
<tr>
<td>Material and methods</td>
<td>16</td>
</tr>
<tr>
<td>Clinical material</td>
<td>16</td>
</tr>
<tr>
<td>Chemicals</td>
<td>16</td>
</tr>
<tr>
<td>Cells</td>
<td>16</td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td>16</td>
</tr>
<tr>
<td>Cell culture</td>
<td>17</td>
</tr>
<tr>
<td>Assay of cell growth and survival</td>
<td>17</td>
</tr>
<tr>
<td>Isolation of cell membranes</td>
<td>17</td>
</tr>
<tr>
<td>Determination of protein content</td>
<td>17</td>
</tr>
<tr>
<td>Cell viability assay</td>
<td>17</td>
</tr>
<tr>
<td>Immunoprecipitation</td>
<td>18</td>
</tr>
<tr>
<td>Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)</td>
<td>18</td>
</tr>
<tr>
<td>Western blotting</td>
<td>18</td>
</tr>
<tr>
<td>Comparative genome hybridization (CGH)</td>
<td>18</td>
</tr>
<tr>
<td>Polymerase chain reaction (PCR) and sequencing</td>
<td>19</td>
</tr>
<tr>
<td>Statistical evaluation</td>
<td>19</td>
</tr>
<tr>
<td>Results</td>
<td>20</td>
</tr>
<tr>
<td>Paper I</td>
<td>20</td>
</tr>
<tr>
<td>Paper II</td>
<td>20</td>
</tr>
<tr>
<td>Paper III</td>
<td>21</td>
</tr>
<tr>
<td>Paper IV</td>
<td>21</td>
</tr>
<tr>
<td>Discussion</td>
<td>22</td>
</tr>
<tr>
<td>References</td>
<td>26</td>
</tr>
</tbody>
</table>
### ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CGH</td>
<td>Comparative genome hybridization</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic myeloid leukemia</td>
</tr>
<tr>
<td>CTL</td>
<td>Cytotoxic T lymphocyte</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epithelial growth factor receptor</td>
</tr>
<tr>
<td>ER</td>
<td>Endoplasmatic reticulum</td>
</tr>
<tr>
<td>GIST</td>
<td>Gastrointestinal stromal tumors</td>
</tr>
<tr>
<td>HLA</td>
<td>Human leukocyte antigen</td>
</tr>
<tr>
<td>HPF</td>
<td>High power field</td>
</tr>
<tr>
<td>IGFBP</td>
<td>Insulin growth factor binding protein</td>
</tr>
<tr>
<td>IGF-1R</td>
<td>Insulin-like growth factor-1 receptor</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>IRS</td>
<td>Insulin receptor substrate</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>MHC</td>
<td>Major histocompatibility complex</td>
</tr>
<tr>
<td>MLN</td>
<td>Mean of largest nucleoli</td>
</tr>
<tr>
<td>PAS</td>
<td>Periodic acid-Schiff</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PDGFR</td>
<td>Platelet derived growth factor receptor</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphatidylinositol-3 kinase</td>
</tr>
<tr>
<td>PKB/Akt</td>
<td>Protein kinase B</td>
</tr>
<tr>
<td>SCF</td>
<td>Stem cell factor</td>
</tr>
<tr>
<td>SDNA</td>
<td>Standard deviation of the nucleolar area</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulphate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>TAA</td>
<td>Tumor associated antigen</td>
</tr>
<tr>
<td>TM</td>
<td>Tunicamycin</td>
</tr>
<tr>
<td>VEGFR</td>
<td>Vascular endothelial growth factor receptor</td>
</tr>
<tr>
<td>WB</td>
<td>Western blotting</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

I want to thank everyone who has in different ways helped me during the course of this thesis

Stefan Seregard, my tutor, for introducing me to the scientific world of uveal melanoma, for his great stylistic, statistical and executive skills but above all for his great encouragement, warmth and generosity.

Olle Larsson, my tutor, for generously letting me share the lab resources, for his great integrity and vast scientific knowledge, for enthusiastically receiving my new results, supplementing these with interesting new ideas.

Rolf Kiessling, who helped me in every way almost like a tutor, for his great scientific skill, inspiring guidance and never failing interest.

Leonard Gîrnița, my great support in the lab, for his patience in teaching me new lab techniques, even if he had taught me the same thing several times before.

Eva Dafgârd-Kopp, my friend and colleague, who persuaded Stefan and Olle to let me participate in this project.

Gunnar Lemnerstrand, and Bo Philipson for their kind support and encouragement

Bertha Brodin, for sharing with me all her knowledge concerning PCR and primers

Sakari Knautila, Armando Bartolazzi, Elena Levitskaya, Soldano Ferrone, Martine Jager, Arne Östman for stimulating collaborations

Ada Gîrnița, Maria Törnqvist, Yuntao Xie, Gunnar Nilsson, for answering all my questions and helping me out when time was short.

Margareta Rodensjö, for all the help and patience concerning the immunohistochemical stainings

Berith Spångberg, Margareta Oskarsson, Carina Zahn, Kristi Oscar, Anki Frecot, Ylva Lagerquist, Birgitta Grundstroom and Maud Leindahl for always helping me with a smile even when I asked for help “in the last minute”

Ulla-Britt Schützler-Pettersson and Britt Marie Karlhed for valuable help and advice.

Gabor Koranyi, for your “temporary” help when my half-term seminar was lost in cyber space.

Andreas Mårtensson, Ingrid Ludwigs and Fredrik Ellwén for all the instant, valuable computer help

Lennart, for sharing his surgical knowledge and for all encouragement and friendship.
Erik, for encouraging me all the way through medical school and for always giving me sound advices during the work with this thesis.

Agnes, for all the time you spent listening to me rehearsing my first presentation and for the help when the first ALF application felt like a mountain to climb.

Anna, for long nice encouraging telephone calls, Irma, for friendship and valuable advices concerning writing the summary, Eva, for endless discussions over a cup of tea, Frank, a friend to turn to when everything sometimes felt hopeless, Anne, for giving me never ending advices in “life-wisdom”, Anna, my mate in the same “house-maintenance” boat, Annika, for introducing me to “night-club life”, Anna & Erik for encouragement and several nice dinners, Ingela & Bette, my supporting neighbours.

To my family for love and support.

The work was partly supported by grants from Cancerföreningen i Stockholm/ Konung Gustav V:s Jubileumsfond, Cancerfonden, Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för Synskadade, Stiftelsen Synfrämjandets Forskningsfond, Karin Sandqvists stiftelse, Karolinska institutet, Carmen och Bertil Regnérers Stiftelse för forskning inom Området Ögonsjukdomar.
INTRODUCTION

Anatomy, history and treatment

Uveal melanoma is a rare malignancy that threatens both sight and life. Malignancies are not merely a disorder of individual cells. Transformed cells grow into tumor masses, and they invade and metastasize through surrounding tissues. Knowledge of the molecular basis for these complex processes is important for understanding the natural history of malignant disease.

The uveal tract is the pigmented vascular coat of the eye consisting of the iris, ciliary body and choroids. It is composed of many blood vessels, a variable number of melanocytes, supporting connective tissue and nerves. (Fig 1).

![Diagram of the eye showing the iris, ciliary body, and choroid](image)

**Fig. 1.** The uveal tract is composed of the iris, ciliary body and the choroid (black).

Uveal melanoma has had a variety of descriptive names: melanosarcoma for tumors of spindle cell type; melanocarcinoma for tumors of epitheloid cell type; leuкоsarcoma for amelanotic varieties; angiosarcoma for highly vascular tumors; and giant cell sarcoma for anaplastic tumors containing giant cells, often multinucleated. In the last decades the term uveal malignant melanoma has been used and is recommended by the World Health Organization.
Melanocytes are present in the uvea of the eye and in the retinal pigment layer having migrated as melanoblasts from the neural crest. Further locations of neural crest derived melanocytes are in the inner ear, the skin, the hair follicles and the leptomeninges. Uveal melanocytes are involved in the pathogenesis of a variety of eye diseases, the most important of which is malignant melanoma the most common primary malignant intraocular tumor in adults, with an annual incidence of approximately six cases per million per year in Caucasians (Strickland et al. 1981) (Osterlind 1987) (Egan et al. 1988). The incidence in whites is eight times that in blacks and three times greater risk than Asians (Egan et al. 1988). This could point to the causal role of ultraviolet (UV) light in tumorigenesis (Holly et al. 1990) (Sahel et al. 1997). In contrast to these findings, however, is the fact that the incidence of uveal melanoma compared with cutaneous melanoma has not increased during the last 40 years (Bergman et al.) (Dolin et al. 1994) and a higher incidence is not found in the most light-exposed areas of the eye (Schwartz et al. 1997). Therefore the role of UV exposure in the causation of uveal melanoma is controversial. Although uveal and cutaneous melanoma are from similar embryological origin, they differ in biological behavior. Choroidal and ciliary body melanomas metastasize hematogenously and preferentially to the liver in 95%, (Callender 1931) (Einhorn et al. 1974) (Raivio 1977) (Char 1978) (Zimmerman et al. 1983) (Albert et al. 1992). In comparison with skin melanoma which is reported to metastasize to the liver in 4 and 13 %, respectively. (Das Gupta et al. 1964) (Magnus 1977). The liver frequently is the sole site of metastasis in uveal melanoma, (Jensen 1970) while cutaneous melanoma spreads preferentially to adjacent lymph nodes and single organ metastasis is extremely uncommon (Magnus 1977) (Stehlin et al. 1967). There are no demonstrated lymphatics within the uveal tract or in the posterior orbit, although it has been reported lymphatic spread through lymphatics in the conjunctiva from uveal melanoma (Dithmar et al. 2000). This predominance of liver involvement in uveal melanoma is in clear contrast to cutaneous melanoma, where the incidence of liver metastasis is lower, usually 15-20 % (Meyers et al. 1998). Other sites of metastasis include the lungs (30-35%), bones (20-25%), skin (15-20%) and lymph nodes (10-15%), as well as the pancreas, heart, spleen, adrenal glands, gastrointestinal tract, kidneys, ovaries and thyroid. These metastases generally occur in association with liver metastases (Cantore et al. 1994) (Sahel et al. 1997). Brain metastases, commonly observed in cutaneous melanoma, are rarely observed in uveal melanoma.
In the past all patients with uveal melanoma underwent enucleation. Fuchs claimed as early as 1882 that patients with uveal sarcoma (melanoma) almost inevitably died from their disease and that enucleation was the treatment of choice (Fuchs 1882). Today alternative treatment modalities, including radiotherapy, local resection and transpupillary thermotherapy have made it possible to retain eyes. Radiotherapy was first used in 1930 by Moore (Moore 1930). Later the technique was further developed by Stallard who introduced the use of cobalt-60 episcleral plaques (Stallard 1966). Since 1964 the ruthenium-106 episcleral plaques have become widely used, introduced first by Lommatzsch. Today ruthenium-106 as well as iodine-125, palladium-103 and iridium-192 episcleral plaques are used (Packer et al. 1980) (Garretson et al. 1987) (Packer 1987 ) (Finger et al. 1994) (De Potter et al. 1994). Charged-particle irradiation, e.g. proton beam or helium ion radiotherapy, constitutes an alternative treatment modality, however, is it limited by the availability of appropriate therapeutic facilities (Char et al. 1980) (Gragoudas et al. 1980). During a period photocoagulation was used as a therapy but it was associated with frequent tumor regrowth (Barr et al. 1983). Local resection of tumors in the anterior part of uvea has been practiced since the early 1900s (Zirm 1911) (Schubert 1925). Several investigators have during the last decades further developed the technique (Foulds 1973) (Peyman et al. 1984) (Damato et al. 1996) (Char et al. 2001) Since 1995 a new treatment modality, transpupillary thermotherapy, has made it possible to treat smaller lesions with less complications and may be used as adjuvant to brachytherapy (Oosterhuis et al. 1995) (Oosterhuis et al. 1998) (Shields et al. 1998) (Seregard et al. 2001) (Shields et al. 2002).

**Predisposing lesions**

Ocular melanocytosis (Gonder et al. 1982) (Gonder et al. 1981) and nevi (Naumann et al. 1966) (Gass 1977) (Yanoff et al. 1967) are two lesions that predispose to the development of uveal malignant melanoma. In some cases of ocular melanocytosis the hyperpigmentation includes periocular skin and is then referred to as ocudermal melanocytosis or naevus of Ota. Uveal nevi progress to malignant melanoma less frequently than does ocular melanocytosis. Based on the high prevalence of uveal nevi (5% of eyes) and the low incidence of uveal melanoma (7 per 1,000,000 per year), it can be estimated that the rate of transformation of nevi to malignant melanoma is, at most, 1 per 10,000 to 15,000 per year. The difficulty with early detection of choroidal melanoma relates to its clinical similarity to benign choroidal nevus. Shields et al have introduced the mnemonic TFSOM indicating To Find Small Ocular Melanoma, to better help clinicians to identify small choroidal melanomas. The letters in the mnemonic represent, Thickness >2mm, subretinal Fluid, Symptoms, Orange pigment and Margin touching optic disc. Tumors that display one factor have a 38% chance for growth and those with two or more factors show growth in over 50% of cases at 5 years (Shields et al. 2002).
Prognosis

Despite high accuracy of diagnosis the mortality due to uveal melanoma has remained unchanged (Shields et al. 1980) (Shields et al. 1992) (Strickland et al. 1981). The overall prognosis is significantly worse than that of cutaneous melanoma, with the 5 year and 15 year survival rates being 72% and 53% respectively (Diener-West et al. 1992) (Gamel et al. 1993). Approximately 40% of patients with posterior uveal melanoma develop metastatic melanoma to the liver within 10 years after initial diagnosis and treatment (Shields et al. 1991). It is well known that the incidence of metastases at the time of diagnosis is very low, only 2-3%, using conventional methods as liver enzymes and liver scans (Pach et al. 1986) (Wagoner et al. 1982). This fact has made some authors suggest that removal of the primary tumor by enucleation may actually promote the dissemination of malignant cells (Zimmerman et al. 1978). In order to lower melanoma-related mortality, it is essential to prevent metastatic disease. This calls for early detection and for the development of reliable prognostic factors. The median survival after clinical diagnosis of hepatic metastasis is extremely poor. The median survival time after diagnosed metastatic spread is less than seven months (Rajpal et al. 1983) (Seddon et al. 1983) (Kath et al. 1993) it is assumed that tumor dissemination occurs prior to primary tumor therapy. The metastatic tumor cells are considered to be “dormant” for a period as long as 40 years after the initial diagnosis (Coupland et al. 1996).

Prognostic factors

Tumor location

Uveal melanoma can arise in the iris, the ciliary body or the choroid. Iris melanomas (3% of cases) are relatively small when diagnosed and treated (Jensen 1970) (Shields et al. 2001). Iris melanoma has the lowest 5-year mortality rate with 2-3% (Geisse et al. 1985). Ciliary body melanoma has a worse prognosis compared to the others (Seddon et al. 1983). Although ciliary body melanomas tend to be larger at the time of diagnosis compared with choroidal melanoma it has been established that the poor prognosis is independent of tumor size and cell type (Seddon et al. 1983) (McLean et al. 1977).

Extrascleral extension

The presence of extrascleral extension is observed in about 8% of enucleated eyes (1998). In such cases the 10-year mortality is doubled to about 75% compared with cases with no extrascleral extension (Seddon et al. 1983)

Tumor size

Various measurements have been used to represent the tumor size. In a meta-analysis of eight published reports on mortality rates of uveal melanoma following enucleation, uveal melanomas were classified into three groups based on diameter and height (Diener-West et al. 1992). The study confirmed that tumor size at the time of enucleation is a major prognostic factor.
<table>
<thead>
<tr>
<th>Category</th>
<th>Factor</th>
<th>Outcome</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor location</td>
<td>Iris</td>
<td>10 year mortality</td>
<td>6%</td>
<td>Shields et al, 2000</td>
</tr>
<tr>
<td></td>
<td>Ciliary</td>
<td>5 year mortality</td>
<td>53%</td>
<td>Seddon et al, 1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 year mortality</td>
<td>22%</td>
<td>Gunduz et al, 1999</td>
</tr>
<tr>
<td></td>
<td>Choroidal</td>
<td>5 year mortality</td>
<td>14%</td>
<td>Seddon et al, 1983</td>
</tr>
<tr>
<td>Extrascleral extension</td>
<td>Absent</td>
<td>10 year mortality</td>
<td>37%</td>
<td>Seddon et al, 1983</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>10 year mortality</td>
<td>75%</td>
<td>Seddon et al, 1983</td>
</tr>
<tr>
<td>Size</td>
<td>Small</td>
<td>5 year mortality</td>
<td>16%</td>
<td>Diener-West et al, 1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 year mortality</td>
<td>3%</td>
<td>Shields et al, 1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 year mortality</td>
<td>1%</td>
<td>COMS, 1997</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>5 year mortality</td>
<td>32%</td>
<td>Diener-West et al, 1992</td>
</tr>
<tr>
<td></td>
<td>Large</td>
<td>5 year mortality</td>
<td>53%</td>
<td>Diener-West et al, 1992</td>
</tr>
<tr>
<td>Cell type</td>
<td>Spindle</td>
<td>15 year mortality</td>
<td>20%</td>
<td>McLean et al, 1982</td>
</tr>
<tr>
<td></td>
<td>Mixed</td>
<td>15 year mortality</td>
<td>60%</td>
<td>McLean et al, 1982</td>
</tr>
<tr>
<td></td>
<td>Epitheloid</td>
<td>15 year mortality</td>
<td>75%</td>
<td>Shammas et al, 1977</td>
</tr>
<tr>
<td>Proliferative activity</td>
<td>Low</td>
<td>6 year mortality</td>
<td>15%</td>
<td>McLean et al, 1977</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>6 year mortality</td>
<td>43%</td>
<td>McLean et al, 1977</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>6 year mortality</td>
<td>56%</td>
<td>McLean et al, 1977</td>
</tr>
<tr>
<td>PC-10</td>
<td>Low</td>
<td>10 year mortality*</td>
<td>16%</td>
<td>Seregard et al, 1996</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>10 year mortality*</td>
<td>60%</td>
<td>Seregard et al, 1996</td>
</tr>
<tr>
<td>Vascular patterns</td>
<td>Absent</td>
<td>10 year mortality</td>
<td>10%</td>
<td>Folberg et al, 1993</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>10 year mortality</td>
<td>50%</td>
<td>Folberg et al, 1993</td>
</tr>
</tbody>
</table>

* Modified after cumulative 10-year survival proportion

**Table** Clinical and histopathological prognostic factors in uveal melanoma.
Modified after Singh et al, 2001

Cell type

In 1931 Callender proposed a classification system for uveal melanoma based on cell type (Callender 1931). McLean subsequently modified the system (McLean et al. 1983). Uveal malignant melanomas are divided into three main cytological types: spindle, mixed and epitheloid. Spindle cell tumors have a better prognosis than either mixed or epitheloid cell uveal melanomas (McLean et al. 1994). Since characterization of cell type is subjective, morphometric criteria have been proposed. The standard deviation of the nucleolar area (SDNA) is prognostically significant (Seddon et al. 1987). However, measurement of SDNA requires specialized equipment and is time consuming. The measurement of the mean of the diameters of the 10 largest nucleoli, mean of largest nucleoli (MLN) is a more simple method and provides similar prognostic information (Gamel et al. 1992).
Proliferative activity

Proliferative activity as measured by the number of mitoses seen per high power field (HPF) or by looking at the immunoexpression of PC-10 appears to be of prognostic value in some studies (McLean et al. 1977) (Seregard et al. 1996). In a study of 217 uveal melanomas McLean et al observed that tumor mitotic activity correlated with mortality. Tumors with low mitotic activity (0-1 HPF) had good prognosis, with a 6-year mortality of 15% compared with 56% in tumors with high mitotic activity (9-48 HPF) (McLean et al. 1977). Seregard et al showed in their study that the PC-10 count could be of prognostic value in uveal melanoma when adjusting for the effect of MLN and vascular patterns (Seregard et al. 1998).

Vascular patterns

Studies on pathology slides have suggested that the presence of microcirculation architecture (vascular patterns) is a strong prognostic factor for metastatic death (Folberg et al. 1992) (Rummelt et al. 1995). Histopathology slides from paraffin embedded blocks are stained with modified periodic acid-Schiff reagent to evaluate the vascular patterns. Nine types of microcirculation architecture have been described, including: incorporation of normal vessels into the tumor, avascular zones, PAS-positive parallel vascular channels without and with cross linking, arcs with and without branching, loops, networks (defined as a focus of at least three back-to-back loops) and silent pattern (avascularity) (Folberg et al. 1993). Folberg et al reported in multivariate Cox models that loops and networks were independently associated with mortality from metastatic melanoma (Folberg et al. 1993). The association between vascular patterns and death from metastatic melanoma have also been found by other investigators (Sakamoto et al. 1996) (Makite et al. 1999). Recently, it was reported that not just only loops and networks are associated with an adverse prognosis; also other angiographic patterns may reflect an aggressive tumor behavior (Folberg et al. 2001).

Immunology and eye

The unique immunological characteristics of the anterior chamber of the eye have been recognized for over a century (Niederkorn 1990) (Streilein 1995). Histoincompatible tissue grafts survive for extended periods within the anterior chamber of the eye, yet are promptly rejected when transplanted to extraocular sites. Although it was previously believed that immunological privilege was restricted to the anterior chamber, later evidence clearly indicates that the posterior compartments of the eye also possess immunological properties similar to the anterior chamber (Jiang et al. 1993) (Jiang et al. 1994).

CD8+ T-cells play a major role in the antitumor associated antigen immune response (Ferrone et al. 1995). However, abnormalities in the major histocompatibility complex (MHC) class I antigens are frequently found in human malignant cells, which has set the focus on the control of tumor growth by tumor associated antigen (TAA)- specific CD4+ cells (Rees et al. 1999). The HLA class I molecules (HLA-A, B and C) assemble in the endoplasmatic reticulum (ER) and the HLA class I heavy chain and the \( \beta \)-microglobulin (\( \beta \)-m) are then transported via the trans-Golgi apparatus. The resulting trimolecular HLA class I complex is then expressed on the cell surface for presentation to CD8+ cytotoxic T lymphocytes (CTL) (Fig.2)
Fig. 2. Human leukocyte antigen (HLA) class I processing and presentation. The tumor peptides are translocated to the endoplasmatic reticulum (ER) where they are loaded onto HLA class I molecules. HLA class I heavy chain-β2-microglobulin-tumor peptide complex exit the ER and travel to the cell surface. Tumor peptides are presented to T cell receptors on cytotoxic T lymphocytes (CTLs). HLA class I downregulation can result in lack of tumor cell recognition by CTLs. Tumor cells control natural killer (NK) cell recognition through the interaction of HLA class I antigens. HLA class I downregulation eliminates a negative signal and results in the activation of cytotoxicity by NK cells.

HLA class II molecules (HLA-DR, DP and DQ) are also assembled in the ER and transported to the cell surface to present peptides derived either from self or foreign antigens to CD4+ T cells. Natural killer (NK) cells are a subset of lymphocytes found in blood and lymphoid tissues and are believed to play an important role in the immune surveillance of virus infections and neoplasms. NK cells selectively lyse tumor cells that do not express one or more HLA class I alleles. It is now becoming clear that when the immune system encounters a new antigen, e.g. a tumor antigen, the outcome may well be tolerance rather than activation (Jenkins et al. 1987). This may be the reason why several immunotherapy trials have had problem with limited responses, since cytotoxic T lymphocytes need an adequate HLA expression level to recognize and kill tumor cells, down-regulation of the expression of HLA molecules on the cell surface may be the answer why the number of durable remissions is low. Down regulation of HLA expression has been demonstrated in many different types of cancer, including skin melanoma (Garrido et al. 1995) (Wang et al. 1996). In uveal melanoma, low expression of HLA-A and –B on the primary tumor has been correlated with
better patient survival (Blom et al. 1997), suggesting a protective role for NK cells which can attack target cells more efficiently in the absence of HLA class I molecules (Storkus et al. 1987) (Liao et al. 1991). HLA class II antigens have been found in a number of malignancies, although with variable frequency (Pellegrino et al. 1982). The role of HLA class II antigens in the immunologic interaction of malignant cells is conflicting (Seliger et al. 2000).

Chromosomal aberrations

It is well known that mutations within the cell genome cause cancer (Tannock et al. 1992). The observation that chromosomal abnormalities are observed in many types of cancer supports this hypothesis (Tannock et al. 1992). Chronic myeloid leukemia (CML) was the first malignancy in which reproducible chromosomal abnormality was described, the Philadelphia chromosome (Ph chromosome) (Rowley 1973) A number of specific, non-random chromosome abnormalities have now been identified in a variety of malignancies since the detection of the Ph chromosome. In skin melanoma a large number of studies have been made concerning cytogenetic changes, in summary, the highest frequencies of aberrations are seen in chromosomes 1, 6, 7, 9 and 11 (Fountain et al. 1990) (Albino et al. 1993) (Thomson et al. 1995) In uveal melanoma, several recurrent chromosomal abnormalities have been described. Monosomy 3, abnormalities of chromosome 6 and/or gain of the q arm of chromosome 8 is observed in most tumors (Horsman et al. 1993) (Prescher et al. 1995) (Sisley et al. 2000). Loss of chromosome 3 and gain of the q arm of chromosome 8 associate strongly with decreased survival of the patient (Prescher et al. 1996) (Sisley et al. 1997). In contrast, chromosome 6 abnormalities are associated with a better prognosis (White et al. 1998).

Growth factors

Growth factors are molecules that participate in the control of cell proliferation. They require specific receptors on the target cell and intracellular signaling pathways to transmit the stimulus to the nucleus, where DNA synthesis takes place preceding cell division.

One family of molecules critical for malignant transformation and metastasis are the peptide growth factors that regulate cell entry into and progression through the cell cycle by binding to membrane receptor tyrosine kinases, which transmit signals to the nucleus through an intricate network of signaling molecules (Pardee 1989) (Yarden et al. 1988) (Pawson 1995) Two such subfamilies are the insulin receptor (IR) and the platelet derived growth factor receptor (PDGFR) subfamily. The major feature that separates members of the IR subfamily from most other receptor families is that they exist on cell surface as disulphide linked dimers and require domain rearrangement on binding ligand, rather than receptor oligomerisation, to initiate signal transduction.

One member of the IR subfamily is the insulin-like growth factor-1 receptor (IGF-1R) which is a receptor tyrosine kinase implicated in the induction and maintenance of the transformed phenotype. This heterotrameric receptor consists of two 130 kDa α-chains and two 90 kDa β-chains, with several α-α and α-β disulfide bridges. (Massague et al. 1982) (Ullrich et al. 1986). The ligand binding domain is located on the extracellular α-subunit. The intracellular region of the β-subunit has a binding site for phosphorylation substrates. The IGF-1R ligands include IGF-1, IGF-II and insulin, but it binds IGF-1 with the highest affinity (LeRoith et al. 1992). The primary physiological role of the insulin receptor is to regulate metabolic events, while the IGF-1R activated by its ligands has a major impact on mitogenicity, transformation and survival (Baserga et al. 1997). In addition, signaling by the IGF-I receptor is implicated in
the chemotactic activity of tumor (Brodt et al. 2000). Binding and physiological activities of IGF-1 can be modulated by its association with the IGF-binding proteins (IGFBPs), a family of structurally related proteins that bind both IGF-I and IGF-II with high affinities and regulate their biological accessibility and activity (Sara et al. 1999) (Clemmons 1998). The IGF-1 receptor plays an important role in the regulation of the cell cycle (Baserga et al. 1997). During postnatal development and longitudinal growth, growth hormone functions are mediated via IGF-1R. IGF-1 serum levels are high during childhood, declining progressively after puberty. IGF-1R mRNA levels also decline considerably after puberty, remaining high in selected tissues such as the brain and kidney (LeRoith et al. 1992). Malignant transformation, however, is often associated with up-regulated expression and/or constitutive activation of the IGF-1R (Rubin et al. 1995). In response to ligand binding the intrinsic tyrosine kinase of the receptor is activated, resulting in autophosphorylation of tyrosines on the intracellular portion of the β-subunit and the subsequent tyrosine phosphorylation of several downstream substrates including the insulin receptor substrates (IRS 1-4) and Sbc (Butler et al. 1998) (Petley et al. 1999). The main pathway for the antiapoptotic effect of the IGF-1R is the pathway that through IRS-1 activates phosphatidylinositol 3-kinase (PI3K) (Myers et al. 1993) and through Akt/ protein kinase B (PKB) induces phosphorylation of BAD (Datta et al. 1997). However alternative pathways have also been found for protection of apoptosis that are independent of the IRS-1 pathways. The pathways suggested are one through mitogen-activated protein kinase (MAPK) activation and another through the activation of Raf-1 and its translocation to the mitochondria (Fig. 3) (Peruzzi et al. 1999). Several lines of evidence implicate IGF-1 and IGF-1R in malignant progression. Increased expression of IGF-1, IGF-1R, or both has been documented in many human malignancies including cutaneous melanoma (Kanter-Lewensohn et al. 1998)
Fig. 3. Simplified presentation of the IGF-1R signaling pathways. The activating of the IGF-1R phosphorylates a number of adaptor proteins and thereby triggering the two major signaling cascades, the MAP-kinase and the PI3-kinase pathways.

Another transmembrane receptor tyrosine kinase is the proto-oncogene c-kit. C-kit is related to the PDGF family (Yarden 1987). Protein activation through the kit ligand (also called stem cell factor (SCF), steel factor or mast cell factor) results in phosphorylation of the receptor as well as other proteins (Williams 1990) (Zsebo et al. 1990). Kit is expressed by and critical in the development of melanocytes, mast cells, hematopoetic stem cell, germ cells and the interstitial cells of Cajal (Funasaka et al. 1992) (Natali et al. 1992) (Larue et al. 1992) (Lassam et al. 1992) (Huiizinga 1995). In embryonic development, c-kit is important for normal melanocyte development and proliferation (Yoshida et al. 1993) (Zakut et al. 1993), and e.g. mutations in c-kit or its ligand results in white spotting in mice and humans (Geissler et al. 1988) (Spritz et al. 1993). In addition, injection of anti-KIT antibodies into pregnant mice results in white spotting in offspring (Yoshida et al. 1993). Because of the established relationship of c-kit and its ligand with melanogenesis, the role of this proto-oncogene in the development and progression of human malignant melanoma has become of interest. Specific mutations in the c-kit gene have been found in myeloproliferative disorders (Nakata et al. 1995), mast cells neoplasms (Nagata et al. 1995), seminoma (Tian et al. 1999) and in acute myeloid leukemia (Gari et al. 1999). Mutations in the juxtamembrane domain (exon 11) of the c-kit gene have been shown in gastrointestinal stromal tumors (GISTs) (Hirota et al. 1998) and in a mast-cell leukaemia cell line (Furitsu et al. 1993). The juxtamembrane domain...
mutations have been shown to lead to ligand-independent activation (autophosphorylation) of
the tyrosine kinase of c-kit and have a transforming effect in vitro (Hirota et al. 1998).
Recent data from studies on GISTs have shown that treatment with the phenylamino-
pyrimidine derivate ST1571 inhibits the tumor growth when treated with the drug at well-
tolerated doses

Fig. 4. A schematic drawing of c-kit with five immunoglobuline –like domains (Ig 1-5) in the
extracellular ligand binding region, a single transmembrane domain (TM), a juxtamembrane
domain (JM), two intracellular kinase domains (TK1 and TK2). The position for exon 11 is
highlighted.
AIMS OF THE STUDY

To determine which chromosomal aberrations could be involved in the development of metastases in uveal melanoma using CGH technique.

To investigate if the expression of the different HLA classes are correlated to the clinical outcome of uveal melanoma using different monoclonal antibodies.

To evaluate if the IGF-1 receptor is expressed in uveal melanoma and if it is important for tumor growth.

To investigate if the proto-oncogene c-kit is expressed in uveal melanoma and if tumor cell proliferation can be inhibited by the tyrosine kinase inhibitor STI571.
MATERIAL AND METHODS

Clinical material

We used paraffin-embedded archive material from patients treated solely by enucleation. The specimens were submitted from 1970 to 1985. The patients age ranged from 23 to 87 years. In addition fresh frozen samples were used, these were submitted from 1997 to 1999. The patients were selected to form two groups: survivors (alive 15 years or more after enucleation without signs of metastatic disease) and dead (died of metastatic melanoma) (paper I, II and III).

Chemicals

Cell culture reagents were from Gibco. Fluorescein-isothiocyanate-conjugated dCTP and dUTP were from DuPont, (Boston, MA, USA). All other chemicals unless stated otherwise were from Sigma (St Louis, MO, USA). The following antibodies were used: anti HLA-A10, -A28, -A29, -A30, -A31,-A32,-A33 heavy chains and virtually all HLA-B heavy chains (HC-10), anti-β2-m (L368), anti-HLA class II (LGII-612) were developed and characterized as described elsewhere (Stum et al. 1986) (Lampson et al. 1983) (Temponi et al. 1993), anti-CD44 (IM-79, American Type Culture Collection, Rockville, USA), a monoclonal antibody to the β subunit of the IGF-1R phosphotyrosine (PY99) and a polyclonal antibody to IGF-1R (N-20, SDS, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) a mouse monoclonal antibody against human IGF-1R (d1R-3, Oncogen Science, NY, USA). A mouse monoclonal antibody directed to the human c-kit (CD117) was purchased from Dako (CA, USA). STI571 was obtained from Novartis (Basel, Switzerland).

Cells

Four cell lines, obtained from human primary uveal melanomas (OCM-1, OCM-3, Mel-202 and 92-1), were used. They were kindly provided by Dr Martine J. Jager (Leiden University Medical Center, Leiden, The Netherlands).

Immunohistochemistry

Immunostaining was performed using the standard Avidin-Biotin-immunoperoxidase Complex (ABC) method (Vector Laboratories, Burlingame, CA, USA), on 4-μm thick sections. Deparaffinized, rehydrated sections were pretreated with microwaves for 10 min in citrate buffer (pH 6.0) (paper III and IV) or digested with 0.05% pronase for 15 min (paper III). No antigen retrieval was performed before the antibody incubation in paper II. Before immunostaining the endogenous peroxidase was blocked with hydrogen peroxidase dissolved in methanol for 30 min. Tissue sections were then rinsed and incubated with blocking serum (1% bovine serum albumin) for 20 min followed by an overnight incubation at 8°C with the primary antibodies. A biotinylated antimouse or antirabbit IgG antibodies were used as a secondary antibody and followed by the ABC. 3’3-diaminobenzidine tetrahydrochloride (DAB) was used as chromogen and counterstaining was performed by Mayer's hematoxylin.

TRIS-PBS (pH 7.6) was used for rinsing between the different steps.
Cell culture

The OCM-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), and the Mel-202, OCM-3 and 92-1 cells in RPMI 1640 supplemented with 10% FBS and 3 mM L-glutamine. Cells were grown in monolayers in tissue culture flasks, maintained in a 95% air:5 % CO2 atmosphere at 37°C in a humidified incubator. For experimental purposes the cells were cultured in 35- or 60-mm plastic Petri dishes. Cells were seeded at a density of 3000-5000 cells/cm² and experiments were initiated when cells had reached subconfluence.

Assay of cell growth and survival

In order to determine DNA synthesis in paper III, cells were cultured in 35-mm dishes and, after the experimental conditions, labeled with [3H]thymidine (1μCi/ml, 5 Ci/mmol) for 4 h. The acid-precipitable material was then taken for scintillation counting as described elsewhere (Carlberg et al. 1996). Cell proliferation was measured by determining the number of cells attached onto the plastic surface of duplicate 35-mm dishes. This was performed by microscopic counting of all cells in ink-marked areas on the dish bottom. By repeating the counting after specified time intervals, changes in the number of attached cells could be followed (Dricu et al. 1997).

Isolation of cell membranes

Preparation of cell membranes was performed essentially as described elsewhere (Gammeltoft 1990). In brief, cells were harvested and homogenized in a buffer containing 0.32 M sucrose, 1 mM taurodeoxycholic acid, 2 mM MgCl₂, 1mM EDTA, 25 mM benzamidine, 1μg/ml bacitracin, 2 mM phenylmethylsulfonyl fluoride, 10μg/ml aprotinin, 10μg/ml soyabean trypsin inhibitor and 10μg/ml leupeptin. After a 10-min centrifugation at 600 x g (4°C) the pellet (containing unbroken cells, nuclei and cytoskeleton) was discarded. The supernatant was then centrifuged at 17,300 x g for 30 min. The resulting pellet, contained cell membranes, and the supernatant represented the intracellular compartment containing endoplasmatic reticulum, Golgi complex and other organelles.

Determination of protein content

Protein content of cell lysates was determined by dye-binding assay (Bradford 1976) with a reagent purchased from Bio-Rad. Bovine serum albumin was used as a standard.

Cell viability assay

In paper III and IV cell proliferation kit II was used (Roche Diagnostic GmbH Mannheim, Germany). The test is based on a colorimetric change of the yellow tetrazolium salt XTT into orange formazan dye by the respiratory chain of viable cells (Roehm et al. 1991). Cells seeded at a concentration of 5000/well in 100 μl medium in a 96-well plate were treated with different drugs in specified concentrations. After 24 h, cells were incubated according to the manufacturer protocol with XTT labeling mixture. After 4 h, the formazan dye was quantified using a scanning multivell spectrophotometer with a 495-nm filter. The absorbance is directly correlated with the number of viable cells. In order to draw the standard absorbance curve, we used untreated cells seeded at concentrations from 1000 to 10,000 cells/well with an
increasing rate of 1000 cells/well. All standards and experiments were performed in triplicates.

**Immunoprecipitation**

Cells were washed twice with phosphate-buffered saline (PBS) and then lysed in PBS/TDS containing the aforementioned protease inhibitors. The lysates were clarified by centrifugation. Protein samples were incubated with 10 μl of each analyzed antibody. To 1 ml lysate was added 15 μl Protein G Plus-Agarose. After overnight incubation at 4°C on a rocker platform, the immunoprecipitates were collected by centrifugation in a microcentrifuge at 2,500 rpm for 15 min. The supernatant was discarded whereupon the pellet was washed four times with 1 ml PBS/TDS. The material was then dissolved in sample buffer for SDS-PAGE.

**Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)**

Protein samples were dissolved in a sample buffer containing 0.0625 M Tris –HCl, (pH 6.8), 20% glycerol, 2% sodium dodecyl sulfate (SDS), bromophenol blue and dithiothreitol. Sample amounts obtained from 50 μg – 1mg total cell proteins were analyzed by SDS-PAGE with a 4% stacking gel and a 10% separation gel, essentially according to protocol the of Laemmli (Laemmli 1970). Molecular weight markers (Bio-Rad) were run simultaneously.

**Western blotting**

Following SDS-PAGE the proteins were transferred overnight to nitrocellulose membranes (Hybond, Amersham) and then blocked for 1h at room temperature in a solution of 5% (w/v) skimmed milk powder and 0.02% (w/v) Tween 20 in PBS, pH 7.5. Incubation with the primary antibody, was performed for 1 h at room temperature. This was followed by three washes with PBS and incubation with a biotinylated secondary antibody (Amersham) for 1 h.

After a 15-min incubation with streptavidin-labeled horse peroxidase, detection was performed by enhanced chemiluminescence. Signal was detected with Hyperfilm-ECL (Amersham).

**Comparative genome hybridization (CGH)**

CGH was performed as described previously (Kallioniemi et al. 1994) (El-Rifai et al. 1997). Tumor DNA and normal reference DNA were labeled by nick-translation with fluorescein-isothiocyanate-conjugated dCTP and dUTP (DuPont, Boston, MA, USA) and Texas-red conjugated dCTP and dUTP (DuPont). The hybridization was analyzed using an Olympus fluorescence microscope mounted to a CCD camera and the ISIS digital image analysis system (MetaSystems, Altusseheim, Germany). Three-color images (green for tumor DNA, red for reference DNA and blue for chromosome counterstaining) were acquired from 8 to 10 metaphases with strong uniform hybridization. Chromosome regions were interpreted as overrepresented when green-to-red ratio was higher than 1.17 (gains) and underrepresented when ratio was lower than 0.85 (losses). A ratio value higher than 1.15 was used to define a high-level amplification.
PCR amplification and sequencing analysis

DNA was isolated from frozen uveal melanoma specimens by standard methods. We used a nested polymerase chain reaction (PCR) method to amplify genomic fragments of exon 11 using primers annealing the intronic regions that flank exon 11 of the c-kit gene. Shortly, 500 ng of genomic DNA was amplified using 5’ (GTATGCCACATCCCAAGTGTT) and 3’ (CCTGACAGACATATAAGGCGAC) primers in a 35 cycles reaction of 94° for 30 sec; 52 ° for 45 sec, and 68 ° for 2 min. For the nested PCR, the primers 5’ (CGACTCGATCCATCCCTGCCC); and 3’ (CAAAGGAAGGCACCTGGAGTTCC) were used in a 34 cycles PCR of 94° for 30 sec, 56 ° for 45 sec, and 70 ° for 45 sec. The PCR products were electrophoresed in a 1% agarose gel containing ethidium bromide, and visualized in a UV camera prior to sequencing in an ABI PRISM 310 DNA sequencer using Big Dye terminators (Applied Biosystems, Foster City, CA, USA). The sequences obtained were identified and aligned together with the human c-kit gene sequence obtained from the Genbank (National Center for Biotechnology Information) and analysed using the Sequencher program (Gene Codes).

Statistical evaluation

In paper I the Mann-Whitney test was used to compare the number of aberrations and the frequency of individual changes between different tumor types. In paper II and III time from the date of surgery to death or the end of 1996 was considered censored if the patient was alive at the end of 1996 or had died of any other than a melanoma-related cause. The log-rank test was used to assess survival differences. In paper II the $\chi^2$ test was used to measure association of HLA antigen expression with metastasis development and cell type. In paper II and III the kappa test was used for assessing the inter-observer reproducibility. The significance level was set at 0.05. Calculations were computer based, using Statistica version 5.5 (StatSoft, Tulsa, OK) and MedCalc (MedCalc Software, Mariakerke, Belgium).
RESULTS

Paper I

We studied if there are any genetic differences between metastasizing and non-metastasizing uveal melanoma by using CGH technique. 29 of 35 tumors showed DNA copy number changes. We found that primary uveal melanomas that had metastasized and metastases had significantly more changes than primary uveal melanomas that had not metastasized. Comparison between primary non-metastasizing tumors, metastasizing tumors, and metastases showed that the most common DNA copy number changes were losses of chromosome, 3 (21%/73%/67%, respectively), 6q (7%/40%/83%), 1p (0%/33%/33%), 13q (14%/13%/50%), 8p (14%/27%/0%), and 18 (7%/13%/33%), and gains at chromosome 8q (14%/53%/100%), 6p (29%/20%/17%), 1q (0%/7%/33) and 16p(0%/7%/33). The mean number of DNA copy number changes was significantly higher in the metastasizing tumors and in metastases than in non-metastasizing tumors (P<0.05). There were no significant difference in the DNA copy number changes between metastasizing tumors and metastases.

Paper II

Malignant transformation of cells is frequently associated with abnormalities in human leukocyte antigen (HLA) expression. In this study we immunoperoxidase stained 65 formalin-fixed paraffin-embedded primary uveal melanoma lesions with anti-HLA class I, anti-β2-microglobulin and anti-HLA class II mAbs. We found that HLA class I and β2-m expression were downregulated in 62% (40/65) and 54% (35/65) of the lesions respectively. High levels of HLA class II antigens were expressed in 46% (30/65) of the lesions respectively. HLA class I antigen, β2-m and HLA class II antigen expression in the 65 primary uveal melanoma lesions was associated with poor clinical outcome. Thus, high expression of these markers in the lesions was significantly (P=0.013, P<0.001 and P=0.021, respectively) correlated with development of metastases
Paper III

In an increasing number of malignant cell types IGF-1R has been proven essential for tumorigenesis as well as for the establishment and maintenance of a transformed phenotype. In this study we wanted to elucidate if IGF-1R is expressed in uveal melanoma, and if the expression is correlated to clinical behaviour, cell growth and survival of uveal melanoma cells. We were able to confirm a expression of IGF-1R in uveal melanoma both in paraffin embedded tumor specimens by immunohistochemistry and by Western blotting on fresh frozen samples. Using Kaplan Meier statistical analysis we found a significant association between high IGF-1R expression and death due to uveal melanoma ($P = 0.035$).

In the second part of this study, we investigated the expression of IGF-1R in the three uveal melanoma cell lines OCM-1, OCM-3 and 92-1 and how modulation of IGF-1R expression affected cell growth and survival. We found that inhibition of the IGF-1R activity (tyrosine phosphorylation) was associated with a drastic decrease in uveal melanoma cell viability.

Paper IV

For several malignant tumors the expression of the proto-oncogene c-kit is important in tumor progression. Since a c-kit inhibitor is provided for clinical use the aim of paper IV was to evaluate if c-kit is expressed in uveal melanoma and if it would be possible to inhibit tumor growth by the inhibitor ST1571.

First we investigated the expression of c-kit by immunohistochemistry on paraffin-embedded surgical specimens of 134 cases of primary uveal melanoma. Positive immunoreactivity was found in 84 of the cases. The expression level regarding intensity was scored no, low, medium and high staining as described in Material and methods. To further confirm the results we also investigated the expression of c-kit on eight fresh-frozen samples from primary uveal melanoma, on two uveal melanoma cell lines and six skin melanoma samples by Western blotting using an antibody specific for c-kit (CD117), six of the uveal melanoma cases and both cell lines resulted in a positive signal but none of the skin melanoma samples could be shown to express c-kit. To study the anti-proliferative effects of the tyrosine kinase inhibitor ST1571 we treated four uveal melanoma and two skin melanoma cell lines. Cell proliferation was completely inhibited after 48h by 1µM ST1571 in the uveal melanoma cell lines but not in the skin melanoma cell lines. Chromosomal analysis failed to detect any mutations on exon 11 in this material.
DISCUSSION

Distant metastases, probably seeded before treatment of the primary tumor, could possibly explain the high incidence of tumor related death in uveal melanoma. It is well known that the incidence of metastases at the time of presentation is very low, only 2% (Pach et al. 1986). At present we neither have the techniques to identify the patients who are of greatest risk to develop metastases nor do we have any effective treatment to offer them. It is thus of great importance to find factors that at an early stage can help us identify and treat them.

For the purpose of predicting prognosis based on chromosomal aberrations we screened uveal melanoma samples for DNA copy number changes by CGH and looked at the copy number changes between non-metastasizing and metastasizing tumors. Previous chromosome banding analysis and loss of heterozygosity studies fitted well with our findings that losses of chromosome 3 and gains of chromosome 8 are signs of poor prognosis (Horsthuisen et al. 1992) (Prescher et al. 1996) (Sisley et al. 1997) (White et al. 1998). Two recently published studies have shown that this knowledge may be useful clinically since it is easily possible to use FISH on both fresh frozen material from enucleated eyes (Patel et al. 2002) and on fine needle aspiration biopsies (FNABs) from patients solely treated by radiotherapy (with or without transpupillary thermotherapy) (Naus et al. 2002) for assaying prognostic parameters such as chromosome 3 loss and/or chromosome 8q gain. The most common aberration in skin melanoma, loss of chromosome 9p21 which have been suggested to be the familial melanoma gene have not been found in this or in any other published study. Uveal melanoma is not an inherited tumor in most cases. We also found that the frequency of copy number changes is significantly higher in metastasizing tumors and metastases than in non-metastasizing tumors. The loss of 1p, with minimal overlapping region at 1p21-p23, could only be detected in metastasizing tumors suggesting that this region may harbor a tumor suppressor gene (TSG) important for tumor progression. Deletions of 1p are common in several other human neoplasms, but to my knowledge has no TSGs of any importance for uveal melanoma yet been mapped to this specific region. Presence of chromosome 6 abnormality has been observed to improve prognosis (White et al. 1998). We found a significantly higher frequency of chromosome 6q losses in metastasizing primary tumors and metastases than in non metastasizing tumors and a trend towards more gains of 6p in non-metastasizing tumors.

Aberrations on chromosome 6 could possibly be correlated to the human leukocyte antigen (HLA) expression since the genes for the HLA class I α chain (the β2-microglobulinβ2m) gene is localized to chromosome 15q22) and HLA class II are both located in the 6p21.3 region on the short arm of chromosome 6. However has that connection been refuted in both skin and uveal melanoma (Jiminez et al. 1999) (Metzelar-Blok et al. 1999).

In skin melanoma and many other human tumors, changes in the expression and/or function of HLA class I antigens may provide malignant cells with mechanisms to escape from T-cell recognition and destruction (Garrido et al. 1997) (Hicken et al. 1999) (Koopman et al. 2000) (Marincola et al. 2000). This abnormality might adversely affect the clinical course of the disease and the outcome of immunotherapy. The association between high HLA class I antigen expression in primary lesions and poor prognosis we, as well as Blom et al (Blom et al. 1997), found in patients with uveal melanoma is contrary to what has been found in skin melanoma and in other types of malignancies. In uveal melanoma, the association of low HLA class I antigen expression in primary lesions with favorable clinical course of the disease may reflect the susceptibility to NK cell mediated lysis of low HLA class I expressing
melanoma cells invading blood vessels, as proposed by Blom et al. (Blom et al. 1997). If this interpretation is correct, NK cells may be particularly important in tumors spreading hematogenously, while playing less of a role in tumors spreading via the lymphatic system. Several studies on mice have confirmed this theory (Algarra et al. 1989; Ma et al. 1995) even though uveal melanoma seems to have evolved other means to escape NK mediated surveillance, including production of a macrophage-inhibitory factor which prevents lysis by NK cells (Repp et al. 2000). HLA class II antigens were detected in a significantly higher percentage of primary uveal melanoma lesions than that reported by Jager et al (Jager et al. 1988). Although one cannot exclude that this reflects differences in the sensitivity of the immunohistochemical assays used in the two studies, we favor the possibility that the low HLA class II antigen expression described by Jager et al (Jager et al. 1988) is caused by the exposure of the uveal melanoma analyzed to x-ray irradiation prior to enucleation. Our interpretation is supported by the correlation found in another study between HLA-DQ expression in a uveal melanoma and a ciliary body localization of the tumor and between a low HLA-DQ and –DP expression and an intact Bruch’s membrane (de Waard-Siebinga et al. 1996). HLA class II antigen expression in primary uveal melanoma lesions has clinical significance, since none of the patients lacking HLA class II antigen expression in their primary lesions (14 cases) died from uveal melanoma. In contrast, 18 of the 30 patients with high HLA class II antigens died from uveal melanoma. It has been demonstrated that HLA class II antigen bearing melanoma cells induce the secretion of immunosuppressive cytokine IL-10 by T cells resulting in T cell anergy (Brady et al. 2000) which may explain the association between high HLA class II antigen expression in primary uveal melanoma lesions and poor prognosis. Alternatively, the observed correlation may reflect the resistance of hematogenously spreading melanoma cells with high HLA class I as well as HLA class II antigen expression to NK cell lysis, since HLA class I and HLA class II antigens may share a common regulatory pathway (van den Elsen et al. 1998) and the expression of these molecules were found to be correlated in our study.

Receptor tyrosine kinases play a role in normal cellular regulatory processes. However, aberrant tyrosine kinase activity can lead to cellular transformation and can be causally associated with tumor maintenance and progression. Previous studies on uveal melanoma have shown that the expression of epidermal growth factor receptor (EGFR) was significantly correlated with death due to metastatic disease and decreased survival (Ma et al. 1998) (Hurks et al. 2000). Although conflicting data also has been reported, stating that the expression of EGFR in uveal melanoma was only due to macrophages (Scholes et al. 2001). In several cell types, IGF-1R has been shown to play a pivotal role in cell cycle regulation, differentiation, apoptosis protection as well as in cell transformation (Harrington et al. 1994) (Kalebic et al. 1994) (Prager et al. 1994) (Resnicoff et al. 1994) (Shapiro et al. 1994) (Baserga 1995) (Resnicoff et al. 1995) (Sell et al. 1995). Furthermore, a high expression has been shown to be correlated with a poor clinical outcome in certain cancers. Xie et al recently demonstrated that metastatic dissemination of synovial sarcoma, a highly malignant soft tissue tumor, was significantly correlated with a high expression of IGF-1R in the localized tumor, as assayed by both RT-PCR and Western blotting (Xie et al. 1999). Egan et al have reported the importance of IGF-1 and its serum binding protein, IGFBP-3, both of which were found to independently predict metastasis in choroidal melanoma (Egan et al. 2000). However, as stated by Baserga, IGF-1 (or IGF-2) can stimulate the growth of tumors but it is the receptor that defines the outcome, and presence of an IGF-1R is obligatory for malignant transformation (Baserga 1999).

From our study we can conclude that IGF-1R is expressed to a variable extent in uveal melanoma (based on a selected sample) and that high expression of IGF-1R is associated with
a decreased survival in this disease. From our study we can also conclude that growth and survival of uveal melanoma cell lines are strongly dependent on IGF-1R expression and activation. Specifically, we have shown that inhibition of N-linked glycosylation induced by treatment with tunicamycin (TM) and lovastatin caused decreased IGF-1R expression, and consequently decreased IGF-1R tyrosine phosphorylation. Subsequently, this induced growth arrest and cell death in the three investigated uveal melanoma cell lines. In this way treatment with TM and lovastatin simulate the effect of growth factor depletion, which in itself induces apoptosis in tumor cells (Evan et al. 1992). It could be argued that lovastatin and TM kill the cells by other mechanism than by down-regulating the IGF-1R. However, as shown in this study and in others (Dricu et al. 1997) (Dricu et al. 1999) (Girmita et al. 2000), the kinetics of the growth inhibition and cell death correlate well with the effects obtained by the decrease in IGF-1R tyrosine phosphorylation using the IGF-1R blocking monoclonal antibody αIR-3 (Fig 4).

**Fig 4.** A scheme showing where lovastatin, tunicamycin and αIR-3 interfere with IGF-1R
Lovastatin is an inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion from HMG-CoA to mevalonate. Tunicamycin, a nucleoside antibiotic, inhibits the glycosylation. αIR-3 is a monoclonal antibody against the binding domain at IGF-1R
Somatostatin and its analogs can inhibit growth by interfering with IGF-1 signaling in normal and malignant cells (Reubi et al. 1995). Down regulation of IGF-1 (Yumi et al. 1997), upregulation of the expression of inhibitory IGF-1-binding proteins (Ren et al. 1992), and inhibition of the mitogenic signalling via the IGF-1R (Grant et al. 1993) (Cattaneo et al. 1996) have been reported as a plausible mechanisms mediating the growth inhibitory effect of somatostatin analog octreotide. Our results, that uveal melanoma expresses IGF-1R and that inhibition of its function leads to growth arrest and cell death, theoretically support the indication of somatostatin IGF-1 inhibition of uveal melanoma.

The proto-oncogene c-kit encodes a transmembrane tyrosine receptor whose expression is lost or upregulated in a wide variety of human malignancies. The kinase activity has been implicated in the patophysiology of a number of these tumors, including GISTs, neuroblastoma and skin melanoma. In skin melanoma, c-kit is expressed in epidermal melanocytes but in primary melanomas loss of the receptor is observed in more invasive lesions, only 30% of them express c-kit (Lassam et al. 1992) (Natali et al. 1992). Contradictory to a previous study, which failed to detect expression of c-kit in the uveal melanoma cell line OCM-1 (Mouriaux et al. 2001), we have shown using both IHC and Western blotting that c-kit is expressed in uveal melanoma. Binding of stem cell factor (SCF) to c-kit results in receptor homodimerization, activation of kit tyrosine kinase activity and resultant phosphorylation of a variety of substrates. Former studies on skin melanoma have shown that c-kit expression is regulated by the transcription factor AP-2 (Bar-Eli 2000). Interestingly, AP-2 has been shown to regulate the expression of both c-kit and IGF-1R (van den Oord et al. 1994) why AP-2 can be an interesting target for future investigation. The tyrosine kinase activity of kit can be activated by mutation of several different exons of the c-kit gene. The juxtamembrane region of kit (exon 11) serves as an antiodimerization domain. Mutations of this domain result in activation of kinase activity by allowing ligand-independent receptor dimerization (Irusta et al. 1998) (Ma et al. 1999). Mutations in the exon 11 of the c-kit gene have been shown in mast cell leukemia cell line (Furitsu et al. 1993) and in GISTs (Hirota et al. 1998). Targeted therapy to inhibit the kinase activity of KIT has been exploited in the successful treatment of GISTs with the phenylpyrimidine STI571 (CGP 57148B, Imatinib mesylate, Gleevec®, Glivec®) (Joensuu et al. 2001). This fact raised the interest whether mutations in exon 11 could be found in uveal melanoma, and if growth arrest could be induced in the uveal melanoma cells by treating them with STI571. We did not detect any mutations in exon 11 of 15 fresh frozen samples. In contrast, we found that treatment with STI571 led to complete cell arrest in all four uveal melanoma cell lines but not in the investigated skin melanoma cell lines. These observations suggest that STI571 may be useful in treatment of metastasizing uveal melanomas overexpressing c-kit.
REFERENCES


Fuchs (1882). “Das Sarcom des Uvealtractus.”


